Mark Cuban and a Texas Candidate Take On Big Medicine

James Talarico wants to break up the companies that set the price of your pills. He is running for Senate in Texas. Mark Cuban is standing next to him. The two men will appear together in Fort Worth on Saturday to talk about a plan that targets hospital systems, pharmacy benefit managers, and the insurers that sit between doctors and patients.

“Mark and I agree to break Big Medicine monopolies,” Talarico said.

Cuban has been in this lane before. He started an online pharmacy in 2022 to cut out the middlemen. He says the current system does not work. “Politicians in Washington have not reduced healthcare costs,” Cuban said.

The plan is simple to state and hard to execute. It calls for antitrust action against vertically integrated healthcare conglomerates. That means PBMs, insurance companies, and hospital networks that own each other. The goal is to lower medical debt, reduce prescription drug costs, and give doctors more control over what medication their patients receive.

Recent reports say 90% of all hospital beds are controlled by large hospital systems. Three pharmacy benefit managers process about 80% of prescriptions nationwide. The names are familiar. CVS Caremark. Express Scripts. UnitedHealth Group and its PBM arm, Optum RX. These are not small players. They move money at a scale that makes most markets look like a county fair.

Talarico’s plan would bar PBMs from hiding pricing data. It would create incentives for generic drug development. It would cap out-of-pocket costs. The pitch is that more transparency and more competition will push prices down. That is the theory. The market has heard versions of this before.

Industry groups say the cure is worse than the disease. The American Hospital Association and the Pharmaceutical Care Management Association argue that current competition already keeps costs in check. AHIP, the health insurance trade group, has made similar points in past fights. They say breaking up integrated systems could raise costs and reduce access. They also say the data on consolidation is more complex than the headline numbers suggest.

I have watched this dance for a long time. The pattern is familiar. A candidate finds a pain point that voters feel every month. A well-known business figure lends credibility. The plan promises to fix what feels broken. The timing is not accidental. This is 2026. The Senate race in Texas is one of the most watched contests in the country. Talarico is running against incumbent Attorney General Ken Paxton. Recent polls show a tight race, with some surveys giving Talarico a small lead. The outcome could matter for which party controls the Senate.

Healthcare costs are a top concern for voters. Affordability sits near the top of most lists. A plan that says it will lower drug prices and medical debt speaks directly to that worry. It also gives a candidate a clear message to run on. The Fort Worth event is part of that message machine.

The details matter more than the slogans. Vertically integrated healthcare companies have grown over the last decade. They combine insurance, pharmacy benefits, and sometimes hospitals under one roof. Supporters say this lowers costs by coordinating care. Critics say it creates monopolies that can set prices with little pushback. The truth is probably somewhere in the middle, but the middle does not make good campaign ads.

PBMs have been a target before. They negotiate drug prices between manufacturers and insurers. They also collect fees that are not always visible to patients or doctors. Talarico’s plan would force them to show their pricing. It would also push for more generic drugs, which are usually cheaper. Capping out-of-pocket costs is a direct relief for patients, but someone has to pay for that relief. The plan does not spell out every funding source. That gap will be filled by opponents quickly.

Cuban’s involvement adds weight. He is not a politician. He is a businessman who says he has tried to fix this problem from the outside. His Cost Plus Drug Company was built to bypass PBMs and sell generic drugs at a markup that covers costs but stays low. He says Talarico’s plan aligns with that mission. Whether it can survive a trip through Congress is a different question.

The Senate race in Texas is a toss-up by most measures. Cook Political Report moved it from Republican-leaning to toss-up in late August. Polls show Talarico ahead by small margins, often within the error range. Independents are breaking for him in several surveys. The race is expensive. Ted Cruz has called it a $200 million fight. Money will flow into ads, ground operations, and legal teams. Healthcare will be one of the main battlegrounds.

I do not know if this plan will pass. I do know that markets price in certainty, not hope. The healthcare sector is large and tangled. Hospital stocks, PBM stocks, and insurer stocks all react to policy signals. A serious push to break up consolidated players would create winners and losers. It would also create years of litigation. The American Hospital Association and the Pharmaceutical Care Management Association will not step aside without a fight.

There is also the question of timing. Announcing a detailed plan two months before an election is a political move. It is meant to draw attention and define the race. Whether it changes votes is another matter. Voters care about costs, but they also care about stability. A plan that promises to upend large parts of the healthcare system can sound like risk to some and relief to others.

Talarico says his faith inspired parts of this effort. He has talked about Jesus in interviews when explaining why he took this on. That is his choice. The policy will be judged on its own terms. The numbers he cites are real. The concentration in hospital beds and prescription processing is real. The dispute over what to do about it is also real.

Markets will watch this closely. So will patients who open their mailboxes and see bills they cannot pay. The Fort Worth event will add more words to the pile. The money will keep moving either way.